BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36728146)

  • 1. Treatment Response to Lycopene in Recurrent Prostate Cancer Confirmed on 18 F-Fluciclovine PET/CT.
    Wu C; Marcus C; Baum Y; Kucuk O; Schuster DM
    Clin Nucl Med; 2023 Apr; 48(4):361-363. PubMed ID: 36728146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
    Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
    AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
    Kim EH; Siegel BA; Teoh EJ; Andriole GL;
    Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best Practices for
    Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
    J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of
    Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
    AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
    [No Abstract]   [Full Text] [Related]  

  • 6. The Clinical Utility of
    Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
    Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Seierstad T; Hole KH; Tulipan AJ; Strømme H; Lilleby W; Revheim ME; Hernes E
    PET Clin; 2021 Apr; 16(2):167-176. PubMed ID: 33648662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
    Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
    J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
    J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-targeted Radiotracers versus
    Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
    Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary Role of 18 F-Fluciclovine PET/CT and 18 F-NaF PET/CT in Detecting Prostate Cancer Metastasis.
    Xu F; Liu F; Chen W
    Clin Nucl Med; 2023 Apr; 48(4):330-331. PubMed ID: 36716502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
    Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
    J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
    [No Abstract]   [Full Text] [Related]  

  • 14. Extraprostatic Uptake of
    Robertson MS; Sakellis CG; Hyun H; Jacene HA
    AJR Am J Roentgenol; 2020 Mar; 214(3):641-648. PubMed ID: 31939697
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of fluciclovine (
    Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
    Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (
    Bhanvadia RR; Woldu SL; Margulis V; Subramaniam RM; Bagrodia A
    Clin Genitourin Cancer; 2019 Feb; 17(1):e184-e186. PubMed ID: 30454969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.